GALT Crosses Above Average Analyst Target
June 18, 2018 at 08:04 AM EDT
In recent trading, shares of Galectin Therapeutics Inc (GALT) have crossed above the average analyst 12-month target price of $8.33, changing hands for $8.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..